Effect of Trimetazidine on Functional Capacity in Patient with Ischaemic Cardiomyopathy (TOFCAPI)

Objective: This study aimed to evaluate the efficacy of trimetazidine on exercise capacity via a six-minute walk test in patients with ischaemic cardiomyopathy and also evaluate the effect of trimetazidine on left ventricular function via echocardiography in the same population. Methods: This prospective observational study, conducted at the National Institute of Cardiovascular Diseases in Dhaka, Bangladesh, enrolled 200 patients with ischaemic cardiomyopathy and a depressed left ventricular ejection fraction (LVEF < 35%). We investigated the effects of modified-release trimetazidine on exercise capacity and left ventricular function in ischaemic cardiomyopathy patients with an LVEF less than 35%. The cohort, was divided into Group 1, which received modified-release trimetazidine alongside standard anti-ischaemic therapy and Group 2, which received standard therapy. Patients were subjected to a year-long study with follow-ups at the 1st and 6th months. Using SPSS software, statistical analysis was used to assess treatment-related effects and baseline comparability. Results: In this study (n = 200) of ischaemic cardiomyopathy patients, the mean age was 58 years, with 76% of the patients being male. All study subjects received GDMT (Guideline-Directed Medical Therapy) for angina and heart failure. Those who received the modified released form of trimetazidine developed lesions during the 1st and 2nd follow-ups, during which the LVEF, LVIDd, and six-minute walk distance significantly improved (p < 0.05). There was a progressive improvement in functional status, which was statistically highly significant at the second follow-up. Conclusion: The findings of the present study demonstrated that the addition of modified-release trimetazidine to GDMT can improve exercise capacity and left ventricular function in patients with ischaemic cardiomyopathy.